- Home
- DERM vs TCRX Comparison
DERM vs TCRX Comparison
Compare DERM & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- TCRX
- Stock Information
- Founded
- DERM 2014
- TCRX 2018
- Country
- DERM United States
- TCRX United States
- Employees
- DERM N/A
- TCRX N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- DERM Health Care
- TCRX Health Care
- Exchange
- DERM Nasdaq
- TCRX Nasdaq
- Market Cap
- DERM 107.4M
- TCRX 98.5M
- IPO Year
- DERM 2021
- TCRX 2021
- Fundamental
- Price
- DERM $6.11
- TCRX $1.35
- Analyst Decision
- DERM Strong Buy
- TCRX Strong Buy
- Analyst Count
- DERM 2
- TCRX 6
- Target Price
- DERM $10.00
- TCRX $9.83
- AVG Volume (30 Days)
- DERM 65.9K
- TCRX 442.7K
- Earning Date
- DERM 03-26-2025
- TCRX 03-05-2025
- Dividend Yield
- DERM N/A
- TCRX N/A
- EPS Growth
- DERM N/A
- TCRX N/A
- EPS
- DERM N/A
- TCRX N/A
- Revenue
- DERM $56,134,000.00
- TCRX $2,816,000.00
- Revenue This Year
- DERM N/A
- TCRX $32.21
- Revenue Next Year
- DERM $36.49
- TCRX $118.35
- P/E Ratio
- DERM N/A
- TCRX N/A
- Revenue Growth
- DERM N/A
- TCRX N/A
- 52 Week Low
- DERM $3.20
- TCRX $1.34
- 52 Week High
- DERM $6.89
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- DERM 60.90
- TCRX 29.10
- Support Level
- DERM $5.51
- TCRX $1.44
- Resistance Level
- DERM $6.84
- TCRX $1.76
- Average True Range (ATR)
- DERM 0.43
- TCRX 0.17
- MACD
- DERM 0.05
- TCRX -0.01
- Stochastic Oscillator
- DERM 60.65
- TCRX 1.82
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.